Navigation Links
HemoShear Co-Founder Presents Recommendations for Funding of Breakthrough Technologies to U.S. House of Representatives Committee on Science, Engineering and Technology
Date:7/26/2013

CHARLOTTESVILLE, Va., July 26, 2013 /PRNewswire/ -- HemoShear, LLC, a leading developer of human-relevant systems for drug development and discovery, today announced that Dr. Brian R. Wamhoff, co-founder of HemoShear, was invited to present his recommendations on improvements to the U. S. government's Small Business Technology Transfer program to stimulate translation of new discoveries from academia to the marketplace.  Dr. Wamhoff's testimony was given on Wednesday at a hearing of the U.S. House of Representatives Committee on Science, Engineering and Technology for the purpose of guiding the draft of new legislation entitled "Innovative Approaches to the Technology Transfer Act of 2013".  Dr. Wamhoff was the only industry representative selected to present to the Committee. 

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

Dr. Wamhoff is currently Vice President of Research and Development for HemoShear LLC, a biotechnology research company that is transforming the productivity and success rates of new drug R&D in the pharmaceutical industry.  He was formerly Associate Professor at the University of Virginia Department of Medicine, Cardiovascular Division, where he co-invented the HemoShear technology with Dr. Brett Blackman.  

"Having transitioned recently from academic researcher to entrepreneur, I benefitted from the creativity and resources that academic environments provide, while also encountering cultural challenges of translating a new technology from a university lab to a commercial enterprise.  My fellow academic researchers would benefit from appropriate incentives to translate their science, yet at the same time they need structure and accountability," said Dr. Wamhoff.

Drs. Wamhoff's and Blackman's paradigm-shifting technology, which became the foundation of HemoShear, is the only technology of its kind that accurately replicates human organ system and disease biology in the laboratory.  HemoShear's human-relevant systems are being rapidly adopted by leading pharmaceutical and biotechnology companies to make better decisions and select drug candidates with superior efficacy and safety profiles.  Several institutes within the National Institutes of Health are funding programs with HemoShear, including the National Heart, Lung and Blood Institute; the National Institute of Diabetes and Digestive and Kidney Diseases; and the National Cancer Institute.

In the past forty years, there has been little progress in development of systems that accurately predict human response to new drug candidates.  As a result, more than 90% of new drugs fail in clinical trials, often after companies have spent hundreds of millions of dollars in late stage clinical trials.  The pharmaceutical industry has been consolidating and is seeking answers to reduce costs and improve success rates for new drugs.  HemoShear has repeatedly demonstrated its ability to predict new drug successes and failures.  The Company aims to improve the industry's return on capital, save billions of dollars by avoiding misdirected research, and bring innovative treatments to patients at lower cost.

Dr. Wamhoff's testimony and further information on the Committee's activities regarding the Small Business Technology Transfer program may be found at the following locations:

http://science.house.gov/sites/republicans.science.house.gov/files/documents/HHRG-113-SY14-WState-BWamhoff-20130724.pdf

http://science.house.gov/press-release/subcommittee-looks-improve-transfer-technologies-lab-market  

http://science.house.gov/hearing/subcommittee-research-and-technology-improving-technology-transfer-universities-research

About HemoShear, LLC

By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  

For information about HemoShear, please visit www.hemoshear.com.


'/>"/>
SOURCE HemoShear, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HemoShear Announces Advancement of Predictive Drug Safety Systems
2. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
3. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
4. HemoShear Adds Industry Veterans Mehmood Khan and Fred Brown to Board of Managers
5. HemoShear Unveils In Vitro Steatosis System at Annual Meeting of the Association for the Study of Liver Diseases
6. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
7. SynCardia Co-Founder Honored with Pioneer in Transplantation Award at ISHLT
8. Key patent awarded to Adjuvance co-founders for pioneering method of producing rare vaccine component.
9. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
10. Revalesio Presents Data Showing RNS60 Alters Disease Progression in Animal Model of Alzheimers Disease Through the PI3k-Akt Pathway
11. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
Breaking Medicine News(10 mins):